FTC won’t probe PBMs
It won't look into their practices without a clearer proposal.
It won't look into their practices without a clearer proposal.
A new paper finds there is simply no evidence that compounded hormones pose an increased clinical risk compared to FDA-approved products.
Lest you think FDA’s threat to restrict compounded hormones (based on that deeply flawed NASEM report) was idle talk, check out the letter the agency sent to 22 members of Congress.
It's issued an alert to patients and providers.
Where does APC stand? Our leadership explains.
The discussion, with FDA CDER officials, covered a lot of ground.
High-fives to Ryan DeGuzman and Kaitlin Martin!
For the entire month of February, Topi-Click is matching every new contribution dollar-for-dollar up to $10,000.
We’ve even got a great deal: If more than three folks from the same pharmacy team register, we’ll give all three a 15% discount!
APC and NCPA‘s briefing explained USP’s proposal to restrict beyond-use dates in Chapters <795> and <797> — and the ramifications for patients.
Florida Congresswoman Kat Cammack paid a visit to Wells Pharmacy in Ocala, Fla., on January 5.
Members of Congress express concerns to FDA Commissioner Janet Woodcock.
SCOTUS upheld the CMS vaccine mandate — does it affect your facility?
APC, APhA, and NCPA made the request in December.
They may not know about USP’s proposal and the effects on their patients.
In December, APC, APhA, and NCPA sent a joint letter to Brenda Jensen, chair of USP’s Compounding Expert Committee.
Prescribers need to know the potential issues with USP’s proposals for beyond-use dates on compounded medication.
Shawn and Tara pushed back against misinformation about cBHT ... and looked good doing it.
He’s on the December America’s Pharmacist mag.
"Not a creature was stirring," indeed.
22 members of Congress urged FDA to “craft patient-centered policies that preserve treatment options” related to compounded hormones.
Mention this letter to your pharmacy board members and executive director.
It debuted last week.
The Kentucky Society of Association Executives has directed those who want to help to this list of local charity organizations.
How do you think currently proposed revisions to USP Chapters 795 and 797 will affect your patients and pharmacy practice? We need to hear from you, and soon!
One small thing you can do to help promote APC’s campaign to save compounded hormones.
350 pharmacies donated to APC’s effort to save compounded hormones!
The dollars are not yet rolling in for 2022. And it has us worried.
APC’s comment letter was submitted in response to FDA’s proposed Revised Draft Guidance for Industry.